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• Activation of the
thrombopoietin receptor
requires the glycan binding
site and a novel C-terminal tail
of the mutant calreticulin.
Mutations in the calreticulin gene (CALR) representedby deletions and insertions in exon
9 inducing a 21/12 frameshift are associated with a significant fraction of myeloprolif-
erative neoplasms (MPNs). The mechanisms by which CALR mutants induce MPN are
unknown. Here, we show by transcriptional, proliferation, biochemical, and primary cell
assays that the pathogenic CALR mutants specifically activate the thrombopoietin
receptor (TpoR/MPL). No activation is detected with a battery of type I and II cytokine
receptors, except granulocyte colony-stimulating factor receptor, which supported only
transient and weak activation. CALR mutants induce ligand-independent activation of
JAK2/STAT/phosphatydylinositol-39-kinase (PI3-K) andmitogen-activated protein (MAP)
kinase pathways via TpoR, and autonomous growth in Ba/F3 cells. In these transformed
cells, no synergy is observed between JAK2 and PI3-K inhibitors in inhibiting cytokine-
independent proliferation, thus showing a major difference from JAK2V617F cells
where such synergy is strong. TpoR activation was dependent on its extracellular
domain and its N-glycosylation, especially at N117. The glycan binding site and the
novel C-terminal tail of the mutant CALR proteins were required for TpoR activation. A
soluble form of TpoRwas able to prevent activation of full-length TpoR provided that it wasN-glycosylated. By confocal microscopy
and subcellular fractionation, CALRmutants exhibit different intracellular localization from that of wild-type CALR. Finally, knocking
down either MPL/TpoR or JAK2 in megakaryocytic progenitors from patients carrying CALR mutations inhibited cytokine-independent
megakaryocytic colony formation. Taken together, our study provides a novel signaling paradigm, whereby a mutated chaperone
constitutively activates cytokine receptor signaling. (Blood. 2016;127(10):1325-1335)
Introduction
Myeloproliferative neoplasms (MPNs) are clonal disorders that affect
hematopoietic stem cells (HSCs) and lead to a pathologic expansion of
the myeloid lineage, mainly platelets in essential thrombocythemia
(ET), red blood cells in polycythemia vera (PV), or platelets with
collagenfiber formation inprimarymyelofibrosis (PMF).1Thehallmark
of these disorders is the constitutive activation of the JAK-STAT
pathway.2,3 The first and most recurrent mutation was described in
JAK2 (JAK2 V617F), and was found in PV, ET, and PMF patients.
Activating thrombopoietin receptor (TpoR/MPL) mutations
(W515K/R/L/A) are found in ET and PMF patients.4 Recently, mu-
tations were described in the gene encoding the endoplasmic re-
ticulum (ER) resident chaperone, CALR.5,6 These mutations affect
the exon 9 and lead to the loss of its ER retention signal, KDEL, and
the generation of a positively charged andMet-richC-terminal sequence.
CALR mutants have been identified in ET and PMF patients, being
correlated with a marked thrombocytosis and pathologic megakaryocyte
features. Furthermore, expression of the 2most prevalentCALRmutants
type I (52 bp deletion) and type II (5 bp insertion) in a retroviral mouse
model led to an ET phenotype7 (and companion manuscript8). In-
terestingly, for type I CALR mutant, this ET phenotype evolved to
myelofibrosis, in agreement with recent clinical observations.9,10
In the present study,we show thatCALRmutants acquire the ability
to activate TpoR, explaining the phenotype of the disease centered on
megakaryocytes. We detail the requirements for this interaction and
show that pathologic signaling via the JAK-STAT/PI3-K pathways
appears different from that induced by JAK2V617F.
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Materials and methods
DNA manipulations, production of retroviruses
The CALR wild-type, del52, ins5, and Dex9 sequences were cloned into
pMSCV retroviral plasmids with mCherry. cDNAs coding for HA-tagged
cytokine receptors TpoR (and mutants), EpoR, GCSFR, and all other receptors
and JAKproteinswere cloned inpMX-IRES-GFPas described.11TpoRbox1dead
construct was previously described,12 and soluble TpoR was generated by adding
a stop codon atW491. TheTpoRAsnmutantswere as described.13Viral infections
were performed as previously described.11 shRNA against JAK2 and MPL/TpoR
clonedintoPRRLsin-PGK-eGFP-WPRElentiviralvector (Généthon,Evry,France)
were used as previously described.14-16
Cell lines
The murine Ba/F3 cells were grown and infected as described.11 Ba/F3-TpoR,
EpoR, and G-CSFR cell lines expressing the various CALR mutants were
generated after viral infection and sorted for equal (GFP or mCherry) expression
level (FACSAria III; BD Biosciences). g2A JAK2-deficient fibrosarcoma
cells17 were used for transcriptional studies.11
calr2/2murine embryonic fibroblast cells (MEFs) were kindly provided by
Dr Marek Michalak, University of Alberta, Edmonton, Canada.18
Transcriptional assays
Dual luciferase assay was performed in g2A cells transfected with cDNAs
coding for STAT5, JAK2, and the respective cytokine receptor andCALRwild-
type, mutants, or empty vector11; pRL-TK was used as an internal control
(Promega, Madison, WI). Reporters used were Spi-Luc,19 pGRR5, pSRE, and
pFOXO (6xDBE).11 Stimulationswerewith the appropriate cytokine (10 ng/mL
rhTpo [MilteneyiBiotec], 10U/mLrhEpo [Eprex;Hospital pharmacy], 10ng/mL
rhGCSF [Milteneyi Biotec]).
Growth assays
5000 cells per well were seeded in 96-well plates in medium with the indicated
doses of cytokine and assayed at day 3, by the CellTiter-Glo luminescent Cell
Viability Assay reagent (Promega). To determine long-term cytokine in-
dependence of transduced Ba/F3, cells were plated at a density of 250 000/mL,
and live cells were evaluated after 10 days of culture by cell counting using a
Coulter counter.
Cell surface immunoprecipitation
Ba/F3 cells were incubated with anti-HA antibodies (Roche Diagnostics,
Indianapolis, IN) for 1 hour at 4°C, andwashed 3 times and lysed inNP40 buffer
with 100 mM phenylmethylsulfonyl fluoride, 100 mM orthovanadate, and a
cocktail of protease inhibitor. The lysate was incubated with protein G agarose
Figure 1. CALR mutants specifically activate TpoR, leading to cell transformation. g2A cells were transfected with JAK2, STAT5, and CALR wild-type (wt) or the
indicated mutants in the presence of TpoR (A), EpoR (B), and GCSFR (C). Luciferase assay was performed using the firefly reporter, Spi-Luc/STAT5 (STAT5-luc) and
pRL-TK renilla luciferase for normalization. Ba/F3 cells stably transduced with CALR constructs together with TpoR (D), EpoR (E), or GCSFR (F) were cultured for 3 days, in
the absence of cytokines. Positive controls of Epo and GCSF treatment are shown for Ba/F3 EpoR and GCSFR cells, respectively. Relative viability was measured using
CellTiter-Glo technology. Statistical analysis (jmp pro11) was performed by the nonparametric multiple comparisons Steel test with a control group; *P , .05, **P , .01,
***P , .001.
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(Invitrogen, Carlsbad, CA) overnight at 4°C. The beads were washed and
subjected to western blotting with the indicated antibodies.
Coimmunoprecipitation
NP40 extracts from HEK293 cells were transiently transfected with TpoR and
CALR wild-type or del52 by calcium phosphate and incubated with anti-HA
antibodies (Roche) overnight at 4°C. Protein G agarose (Invitrogen) beads were
added and incubated for 2 hours at 4°C. The beadswerewashed and subjected to
western blotting with the indicated antibodies.
Antibodies
Phospho-specific antibodies were from Cell Signaling Technologies, as
described,11 and anti-CALR antibodies were fromMillipore. b-actin (Sigma)
was used as loading control. Antibodies detecting HA were from Roche.
Endo-H digestion
Endo-H (endoglycosidase H) digestion was performed as previously described
on NP40 extracts from Ba/F3 cell lines.12
Patients
This study was conducted in accordance with the Declaration of Helsinki.
CD341 cells from the peripheral blood of ET patients, with different CALR
mutants identified by fragment sizing and Sanger sequencing, were purified by
cell sorting and were transduced for lentiviral delivery ofMPL and JAK2 short
hairpin RNAs. Two days later, sorted cells were evaluated on a serum-free fibrin
clot assay to quantify megakaryocyte colonies in the presence of stem cell factor
alone or with Tpo.20 Effect of short hairpin RNAs on MPL/TpoR and JAK2
mRNA levels wasmeasured by quantitative real-time polymerase chain reaction
in the plated cells.
Split-luciferase (Gaussia princeps) complementation assay
The cDNA of murine wild-type JAK2 was inserted between Notl and Clal
restriction sites of pcDNA3.1/Zeo vector upstream of either the hGluc fragment
coding amino acids 1-93 (hGluc1) or the fragment coding amino acids 94-169
(hGluc2) of Gaussia princeps luciferase as described.21
BOSC 23 cells were transfected and processed as described.22
Confocal microscopy
calr2/2 MEFs grown overnight on coverslips were fixed with 4% para-
formaldehyde for 15 minutes, were permeabilized, and were blocked with 0.5%
Triton X-100 in phosphate-buffered saline containing 100 mg/mL of goat
g-globulin (Jackson Immunoresearch Laboratories [Bio Connect], Huissen, The
Netherlands) for 1 hour at room temperature. Rabbit anti-CALR (Millipore
[Merck Chemicals], Overijse, Belgium) and mouse anti-Calnexin (Abcam,
Cambridge, United Kingdom) were incubated overnight at 4°C followed by goat
anti-mouse IgG coupled to Alexa 568 or goat anti-rabbit IgG linked to Alexa
488 (Invitrogen/Life Technologies, Gent, Belgium). Slides were examined by
Figure 2. Constitutive signaling of TpoR induced by CALR mutants is JAK2-dependent. JAK2 requirement for STAT5 transcriptional activation was tested by luciferase
assay in JAK2-deficient cell, g2A, transfected with CALR wild-type or mutants, STAT5, and TpoR. (A) CALR mutants were unable to induce STAT5 activation downstream of
TpoR in the absence of JAK2. (B) This observation was confirmed by luciferase assay with the TpoR box 1 dead mutant deficient in JAK2 binding. (C) Schematic
representation of Gaussia princeps luciferase complementation assay used to test JAK2 dimerization in HEK293-derived BOSC cells. (D) Close proximity between the
C-terminal kinase domains of JAK2 activation is induced by CALR del52 and ins5 only in the presence of TpoR. Values shown represent the average of 3 pooled independent
experiments, each performed with 3 biological replicates 6 standard error of the mean (SEM). Statistical analysis (jmp pro11) was performed by the nonparametric multiple
comparisons Steel test with a control group; *P , .05, **P , .01, ***P , .001. (E) Immunoprecipitation using anti-HA antibody from lysates of HEK293 cells transiently
transfected with respective CALR (wild-type or del52) and HA-TpoR constructs, followed by western blotting with the indicated antibodies. Phosphorylated form of JAK2
interacted with TpoR only in the presence of CALR del52 but not wild-type. (F) JAK2 (Y1007/1008), STAT3 (Y705), STAT5 (Y694), TpoR (Y626), ERK1/2, (T202/Y204) and
Akt (T308) activation by CALR del52 in Ba/F3 cells in the absence of Tpo. The condition1Tpo for CALR wild-type probed with pY-TpoR, pY-ERK1/2, pT-AKT, and b-actin was
run in the same gel, but before CALR del52 minus Tpo. It had been displaced for symmetry.
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confocal microscopy using a confocal server spinning disc Zeiss platform
equipped with a 3100 objective.
Cell fractionation
calr2/2 MEF cells (5 3 107) stably expressing TpoR and CALR wild-type or
del52 were harvested in 2 mL of homogenization medium (0.25 M sucrose,
1 mM ethylenediaminetetraacetic acid, 3 mM imadazole, pH 7) and homo-
genized on ice with a tight Dounce homogenizer (6 strokes).23
After removal of nuclei and cell debris at 7700 gxmin, subcellular particles
sedimenting at 73 106 gxmin were layered on top of preformed sucrose density
gradients and equilibrated for 1053106 gxmin. Twelve fractionswere collected
from the bottom and analyzed for density and by western blotting. Fractionation
of the 2 cell lines was performed strictly in parallel. Representative data are from
2 experiments.
Inhibitor assays
Ruxolitinib, erismodegib, buparlisib, and panobinostat (SelleckChem); rapamy-
cin and temsirolimus (Tocris); and the other 17 compounds (SynMedChem)
were dissolved in 100% dimethylsulfoxide (Sigma) to prepare 20 mM stocks
except for NVP-BEZ235, which was dissolved to prepare 10 mM stock.
Combination studies were performed24 in the presence or absence of Tpo
(40 ng/mL).Cell viability was determined by CellTiter-Glo (Promega).
Combination index (CI) was calculated using the CompuSyn software
version 1.0 (ComboSyn Inc). CI values of #0.8 show moderate to strong
synergism.25 CIs were calculated as described.24
Results
CALR mutants specifically activate TpoR
CALR is an ER-resident chaperone implicated in the folding of newly
synthetized proteins through binding to their N-glycosylated sites.26
We hypothesized that the CALR mutants associated with MPN
might bind to and activate cytokine receptors, which are highly
N-glycosylated12,13,27 and because MPNs are known to be driven
either by indirect (JAK2V617F) or direct (TpoR W515L/A/K and
S505N) cytokine receptor activation.2 To test this hypothesis, we
measured STAT5 transcriptional activity in g2A cells transiently
transfected with CALR wild-type or mutants along with a cytokine
receptor, such as TpoR, EpoR, and GCSFR, or a battery of type I and II
cytokine receptors.As shown inFigure 1B,CALRmutants donot induce
constitutive STAT5 activation via EpoR. In contrast, they specifi-
cally induce STAT5 constitutive activation downstreamof TpoR and
GCSFR (Figure 1A,C). TpoR-dependent STAT5 activation was
induced by the 2 most common MPN-associated mutants of CALR,
type I (del52) and type II (ins5), but not by an artificialmutant lacking
the entire exon 9 (Dex9). These results were confirmed using a pan
STAT1/3/5 luciferase reporter (pGRR5), but the activation via
GCSFR was shown to be weaker (data not shown). In supplemental
Figure 1A-E (available on theBloodWebsite),we show that noSTAT5
activationbyCALRmutants couldbedetectedvia IL-2R, IL-9R, growth
hormone receptor, leptin receptor, and type I interferon receptors.
We further validated our data by stable transduction of Ba/F3 cells
with TpoR, EpoR, or GCSFR along with wild-type CALR or mutants
(Figure 1D-F). Because Ba/F3 cells are IL3-dependent requiring
cytokines for their growth, we tested the capacity of CALR mutants
to induce autonomous growth. We measured short-term growth of
the stable Ba/F3 cell lines by using Cell Titer Glo assay after 3 days of
IL-3 removal (Figure 1D-F). Long-term autonomous growth was also
studied after 10 days of culture in the absence of cytokine. Although
EpoR did not induce increased short- and long-term autonomous
proliferation inCALR-mutated cells, interestingly, GCSFR supported a
mild increase in short-term growth inCALR-mutated cells, but no long-
term cytokine-independent proliferation was obtained after repeated
Table 1. Combination study using JAK2/JAK1 inhibitor ruxolitinib with a series of serine threonine kinase inhibitors in Ba/F3 cells
expressing TpoR and the indicated CALR mutants
CI, combination index.
Combination index values of 0.9-1.1 are considered additive, values of 0.8 and below show moderate to strong synergism, and values .1.2 are moderate to strong
antagonism for the drug pair tested. Compounds showing no inhibition are in yellow. For synergic combinations, the darkness of green correlates with increased synergy.
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attempts. Although CALRmutants did not induce autonomous growth
in Ba/F3 cells expressing EpoR and GCSFR, cells did respond to their
cytokines (Figure 1E-F). Only TpoR maintained long-term cytokine-
independent cell growth in the presence of both CALR mutants
(Figure 1D-F), as described in the companion paper.8
Altogether, these results suggest that CALRmutants induce strong
and specific signaling via TpoR, leading to increased proliferation and
autonomous growth.
JAK2 is required for TpoR activation by CALR mutants
JAK2 is required for signaling by TpoR, as well as for its traffic and
stability.12,28,29 To test whether JAK2 is required for TpoR activation
by CALR mutants, we performed STAT5 transcriptional assays in the
human JAK2-deficient g2A cells in the absence of JAK2 or using a
TpoR receptor mutant that does not bind JAK2. CALR mutants could
not induce TpoR activation in the absence of JAK2 (Figure 2A).
Furthermore, a TpoR box 1 dead mutant, which is deficient in JAK2
binding,12 was not able to activate JAK-STAT pathway in the presence
of CALR mutants, indicating that the interaction between TpoR and
JAK2 is crucial for signalingbyCALRmutants (Figure 2B). In addition,
we evaluated dimerization of the JAK2 C-terminal kinase domains by
Gaussia luciferase complementation assay21,22 (Figure 2C). We show
that, in transiently transfected HEK293 cells, CALR mutants induce
dimerization of JAK2 C-terminal domains in the presence of
TpoR, but not of EpoR (Figure 2D). This was accompanied by the
phosphorylation of the JAK2 activation loop at Y1007 residue
(Figure 2E). We also show by coimmunoprecipitation assay that
TpoR is associated with phosphorylated JAK2 only when coexpressed
with CALR del52 (Figure 2E). Furthermore, constitutive STAT3 and 5
activation was observed in Ba/F3 TpoR expressing CALR mutants by
western blotting, along with detectable MAPK ERK1/2, and PI3-K
signaling (Figure 2F). Constitutive activation of MAPK and PI3-K
pathways was also seen by luciferase assay with pSRE and 6xDBE
(supplemental Figure 2B-C). Interestingly,CALRmutant30 found in the
MARIMO cell line and exhibiting the same21/12 frameshift was also
capable of activating STAT5 and MAPK (supplemental Figure 2A-B).
Absence of synergy between JAK2 and PI3-K inhibitors in the
case of hematopoietic cell lines coexpressing TpoR and
CALR mutants
We then studied which signaling pathways induced by CALRmutants
were involved in autonomous proliferation of Ba/F3 TpoR cells by
Figure 3. The extracellular domain of TpoR, but not of EpoR, is indispensable for CALR mutants activity. (A) Schematic representation of engineered chimeric
receptors. On the left, chimeric receptor TTE is composed of the extracellular and transmembrane domains of TpoR (in blue) fused to the cytosolic domain of EpoR (in red).
On the right, chimeric receptor ETT is composed by the extracellular domain of EpoR (in red) fused to the transmembrane and cytosolic domains of TpoR (in blue). STAT5
transcriptional activity was measured by luciferase assay in g2A cells transiently transfected with JAK2 and CALR wild-type or mutants in the presence of the chimeric
receptor TTE (B) or ETT (C). Only the chimeric receptor presenting the extracellular domain of TpoR (TTE) is able to support constitutive activity induced by CALR mutants.
Ba/F3 cells stably transduced with CALR constructs together with TTE (D) or ETT (E) were cultured for 3 days without cytokine to measure short-term autonomous growth
using CellTiter-Glo technology. ETT cells were also tested for response to Epo, as positive control. (F) Long-term proliferation (day 10) of Ba/F3 expressing the indicated
chimeric receptors and CALR variants. Values shown represent the average of 3 pooled independent experiments, each performed with 3 biological replicates 6 SEM.
Statistical analysis (jmp pro11) was performed by the nonparametric multiple comparisons Steel test with a control group; *P , .05, **P , .01, ***P , .001.
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using different inhibitors. After 2 days of treatment, cells expressing
mutated CALR (del52 and ins5) show increasing sensitivity toward
ruxolitinib,whencomparedwithwild-typeCALR(supplementalTable1).
This is consistent with reports showing that JAK-STAT pathway
inhibition by ruxolitinib and fedratinib inhibits constitutive signaling
induced by CALR mutants.31-33
Then we tested whether ruxolitinib could synergize with the PI3-K
inhibitors GDC-421, ZSTK474, and BEZ235 (also an mTOR inhib-
itor), as previously shown for JAK2V617F,24 and with a series of
serine threonine kinase inhibitors to block growth of CALRmutants-
expressing Ba/F3 TpoR cells (Table 1). In the absence of Tpo, using the
Chou-Talalay method, no synergy was detected between JAK2 and
PI3-K inhibitors. For del52 CALR mutant specifically, synergy was
detected between JAK2 inhibitor and the mTOR inhibitor temsiroli-
mus. Conversely, synergy between JAK2 and MEK-ERK inhibitors
could be detected in CALR-mutants cells. Synergy was restored in the
presence of Tpo, as described.24 These data indicate that signaling by
CALR mutants depends mainly on JAK2 and MAP-kinase pathways,
in contrast to JAK2V617F, which is heavily dependent on JAK2 and
PI3-K.24,34,35
The extracellular domain and the N-glycosylation sites of TpoR
are indispensable for TpoR activation by CALR mutants
To uncover the mechanism of TpoR activation by CALR mutants,
we generated chimeric constructs in which the extracellular and cyto-
solic domains of TpoR and EpoR were reciprocally fused together
(Figure 3A). Only the chimeric receptor that contained the extracellular
domain of TpoR (TTE) supported constitutive STAT5 activation by
both CALR mutants in transient transfection luciferase assays
(Figure 3B-C). In addition, the TTE receptor was also able to support
short- and long-term cell proliferation of Ba/F3 cells (Figure 3D,F),
whereas ETT did not (Figure 3E-F). Although ETT did not support
constitutive growth induced by CALR mutants, this receptor still
responded to Epo (Figure 3E). Thus, the extracellular domain of TpoR
is absolutely required for activation by CALR mutants.
The TpoR extracellular domain is composed of 4 subdomains (D1,
D2, D3, and D4) (Figure 4A). We generated constructs expressing
TpoRwith onlyD1D2 (TpoRD1D2) orD3D4 (TpoRD3D4).Only the
more membrane-distal region of TpoR (TpoR D1D2) supported con-
stitutive activation by CALR mutants (Figure 4B-C).
Figure 4. The membrane-distal part of extracellular domain of TpoR (D1D2) and its associated N-glycosylation sites control CALR mutant activity. (A) Schematic
representation of TpoR with its extracellular subdomains and the N-glycosylation sites that have been mutated into Q. The more distal subdomains of extracellular domain of
TpoR, namely D1D2, contain 2 N-glycosylated sites annotated N1 (N117) and N2 (N178). The proximal subdomains D3D4 contain two N-glycosylated sites annotated
N3 (N298) and N4 (N358). STAT5 transcriptional activity was assessed by luciferase assay in g2A cells transiently expressing STAT5, JAK2, CALR wild-type, or mutants
together with the following TpoR mutants: TpoR D1D2 (B), TpoR D3D4 (C), TpoR N1234tQ (D), TpoR N123tQ (E), TpoR N124tQ (F), TpoR N134tQ (G), TpoR N234tQ (H),
and TpoR N12tQ (I). Mutant TpoR missing D1D2, rather than D3D4, is unable to support CALR mutant activity (B). Values shown represent the average of 3 pooled
independent experiments, each performed with 3 biological replicates 6 SEM. Statistical analysis (jmp pro11) was performed by the nonparametric multiple comparisons
Steel test with a control group; *P , .05, **P , .01, ***P , .001.
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Wegeneratedmutations in the extracellular domainofTpoR,where
all the 4, 3, or 2 asparagine (Asn) residues were mutated to glutamine
(Gln) (Figure 4A).13 The TpoRmutant devoid of all 4N-glycosylation
sites (TpoRN1234tQ) failed to support STAT5activation in thepresence
of CALR mutants (Figure 4D). When individual Asn residues were
restored inTpoRN1234tQbackground,N117 (N1, themostN-terminal)
residuewas shown tobe themost activating (Figure4H),N298andN358
were not activating, andN178 supportedweak activation only byCALR
ins5 (Figure 4E-G). Consistent with these results, a TpoRmutant lacking
bothN117 andN178 (N12tQ) is completely unable to support activation
by both CALR mutants (Figure 4I). These results show that 2 Asn
residues (N117 andN178) present in D1D2 are key players for TpoR
activation by CALR mutants.
Next, we showed that the soluble extracellular domain of TpoR
(stop codon at W491 upstream of the TpoR transmembrane domain)
acts as a competitor to the full-length TpoR and blocks STAT5
activation by CALR mutants (Figure 5A). Importantly, a soluble
extracellular domain where all the 4 Asn sites were mutated to Gln
failed to exert inhibition (Figure 5B). However, CALR del52 mutant
could still induce activation of the Tpo-binding–deficient TpoRmutant
(D261A/L265A)36 (Figure 5C).
Altogether these results show that activation of TpoR by CALR
mutants is dependent on TpoR N-glycosylation sites, but independent
of the Tpo binding site.
The glycan binding site of CALR del52 mutant is required for
TpoR activation
Because theN-glycosylation sites ofTpoRare required for its activation
byCALRmutants,wemutated theglycanbinding site (Y109F/D135L)37
in CALR del 52 and could show that it does not activate TpoR in the
absence of Tpo (Figure 5D). This supports the notion that the
interaction between CALRmutant and TpoR requires CALR glycan
binding site and the TpoR N-glycosylated sites for TpoR activation
CALR mutants show differential stability, localization, and
TpoR maturation
To study CALR mutants in a cell background devoid of wild-type
CALR,we usedMEFs derived from calr2/2mice. calr2/2MEFswere
transduced with viruses coding for TpoR and CALR wild-type or
mutants and sorted for equivalent levels of GFP (for TpoR) and
mCherry (forCALR).Weassessedbyconfocalmicroscopyandwestern
blotting the level of CALR expression and its stability. In contrast to
wild-type CALR, the CALR mutants were unstable and this was
accompanied with less CALR mutant protein expression (Figure 6A).
Also, we showed that CALR mutants induce tyrosine phosphor-
ylation and nuclear translocation of STAT3, indicating that wild-type
CALR was not required for JAK-STAT activation by CALR mutants
(supplemental Figure 3A).
To define the subcellular localization of wild-type and mutant
CALR, postnuclear fractions were prepared by sedimentation of
homogenates that were partitioned on sucrose density gradients
(Figure 6B). The distributionof allmarkers tested aswell as the density
of each fraction are shown in supplemental Figure 4. The sedimentable
ER-marker, GRP78, equilibrates with CALR wild-type (fraction #5),
but not with CALR del52 (fraction #7), suggesting the dissociation
of CALR mutant from ER (Figure 6B). High-resolution confocal
microscopy was performed in calr2/2MEFs to avoid the interference
of the endogenous CALR. CALR wild type and mutants exhibited
Figure 5. TpoR constitutive activation induced by CALR mutants is abrogated by the TpoR soluble form and requires the glycan binding site of CALR. (A) The
soluble extracellular domain of TpoR acts as a competitive inhibitor of TpoR activation by the CALR mutants as shown by luciferase assay (STAT5 transcriptional activity).
This inhibitory effect is lost when all the N-glycosylated asparagine residues of the soluble TpoR are mutated to glutamine (soluble TpoR-NtQ) (B). (C) The g2A luciferase
assay showed that the TpoR -D261A/L265A mutant, unable to bind Tpo, is activated by CALR del52. CALR del52 mutant unable to bind N-glycosylation modifications (CALR
del52 D135L/Y109F) do not induce TpoR -dependent STAT5 activation (D). Values shown represent the average of 3 pooled independent experiments, each performed with
3 biological replicates 6 SEM. Statistical analysis was performed by the nonparametric multiple comparisons Steel test with a control group; *P , .05, **P , .01.
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different intracellular localizations, ER vs vesicle (ER to Golgi), re-
spectively (Figure 6C and supplemental Figure 3B).Wild-type CALR
colocalized with the ER marker calnexin (Figure 6C, left panel). This
was not the case for del52 or ins5 mutants (Figure 6C, left panel),
which colocalized with ERGIC53 (ER to Golgi intermediate
compartment) (Figure 6C, right panel) and partially with or adjacent
to GM130 (Golgi marker) (supplemental Figure 3B).
We observed maturation defects of TpoR in the Ba/F3-TpoR cells
expressing CALR mutants by western blotting, with the majority of
TpoR remaining EndoH-sensitive (immature, high mannose form). In
contrast, the CALR wild-type promotes EndoH-resistant mature form
of TpoR (Figure 6D). Surface immunoprecipitation of TpoR in Ba/F3
TpoR–expressing cells showed that CALRmutants are associated only
with the immature form of TpoR (Figure 6E).
Spontaneous megakaryocytic progenitor growth in
CALR-mutated ET patients requires TpoR and JAK2
To confirm the involvement of the TpoR/JAK2 axis in the human
disease, we performed in vitro studies using primary cells fromCALR-
mutated ET patients carrying either CALR ins5 or del52 mutations.
As previously reported, we detected spontaneous (Tpo-independent)
growth of megakaryocyte progenitors in such patients.38 CD341 cells
were transduced with lentiviruses expressing either short hairpin RNAs
targeting TpoR/MPL or JAK2 or a scrambled sequence, and GFP
as a reporter marker. Downregulation of TpoR/MPL or of JAK2
gene expression (Figure 7A) led to a significant inhibition of Tpo-
independent colonies (;50% reduction) associated in both types of
CALR mutants (Figure 7B). Our data thus confirm that TpoR and
JAK2 are absolutely required for the phenotype induced by CALR
mutants in primary megakaryocyte progenitors from patients.
Discussion
This study uncovers a novel signaling mechanism in which a cytokine
receptor is activated by a mutant chaperone protein leading to a pheno-
type linked to the lineage-restricted TpoR. We demonstrate that the
2 most common MPN-associated CALR mutants induce constitutive,
Figure 6. CALR mutants modify TpoR stability, maturation, and trafficking. (A) The expression of CALR in calr2/2 MEFs transduced with retroviral constructs expressing
TpoR and CALR wild-type or mutants was assessed by immunofluorescence (top panel) and by western blotting after cycloheximide (30 mg/mL) treatment (bottom panel). (B)
Maturation state of TpoR in Ba/F3-TpoR cells in the presence of CALR wild-type or mutants was assessed by western blotting upon endoglycosidase H treatment or not. (B)
Subcellular fractionation of CALR wild-type and mutant del52 proteins in calr2/2 MEF TpoR cells. The distribution patterns of CALR and GRP78 were shown in the diagram
and the blots. (C) Confocal immunofluorescence microscopy was performed in previously described calr2/2 MEF cell lines and stained with anti-CALN (Calnexin), anti-CALR,
and 4,6 diamidino-2-phenylindole. (D) Maturation state of TpoR in Ba/F3-TpoR cells in the presence of wild-type or mutant CALR was assessed by western blotting upon
endoglycosidase H treatment or not. (E) Western blot analysis of immunoprecipitated N-terminal HA-tagged TpoR present on cell surface, in Ba/F3-TpoR cells expressing
wild-type or mutant CALR. All data are normalized, C being the amount per volume of subfraction, and Ci the corresponding value in the pooled subfractions.
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ligand-independent activation of TpoR, in several systems and with
different read-outs. The interaction between CALR mutants and
TpoR directly leads to close dimerization of JAK2 kinase domain
and its activation. These observations are in accordance with the
results of bone marrow transplantation studies7 and companion
study,8 where CALR mutants induced an ET phenotype, as well as
with TpoR being essential for the megakaryocytic lineage, which is
affected in ET and PMF patients. No other receptor tested could
support activation of JAK-STAT pathway by CALR mutants, except
GCSFR, where activation did not lead to long-term proliferation. It
remains to be determined whether the weak GCSFR effects contribute
to the phenotype or penetrance in the granulocytic lineage.
We show that the extracellular domain of TpoR is crucial for
activation by CALR mutants. Further studies are required for
determining the structural details of exactly how CALR mutants
interact with the TpoR extracellular domain. TpoR N-linked sugars
and CALR glycan-binding domain and the novel tail are required.
Interestingly, unlike most of the cytokine receptors (including the
closely related EpoR),39 TpoR has been shown to be able to signal
from several dimeric interfaces.11,40 Because CALR can bind to
N-glycosylated residues of several proteins,26 the specificity of TpoR
activation cannot be attributed only to the interaction of CALR
mutant to the receptor; rather the CALR mutant might stabilize one
of the many active interfaces of TpoR,11,40 resulting in constitutive
activation of the receptor. del52 and ins5 CALR mutants might
stabilize 2 related, but not identical, active dimeric interfaces of
TpoR, leading to differences in the phenotype, as suggested.41,42
This hypothesis would also explain why CALR mutants are not seen
in other cancers driven by N-glycosylated mutated receptors (eg, EGFR,
EPOR,KIT,FLT3D).6Furthermore, binding of CALRmutant to TpoR
and its activation do not require Tpo-binding.
Recently, the pathogenic effects of CALR mutants were shown to
depend on the length of the stretch of negatively-charged residues that
are retained before the frameshift.10 Type 1–like mutations resemble
del52 CALR, where most of the stretches are deleted; this leads to high
cytosolic calcium levels in megakaryocytes, presumably caused by the
absenceof calciumstorage capacity in theER.10Another type1mutant,
del61 CALR, reported in theMARIMOcell line,30 derived from an ET
patient whowas treatedwith Busulfan,43 also activates TpoR (supplemen-
tal Figure 2A-B). Mutants that preserve stretches of negatively-
charged residues like ins5 do not show calcium defects.10 Further
studies are required to determine whether the higher signaling we
note in the case of del52 CALR is linked to its effects on calcium.
The interaction between TpoR and CALR is not only important in
cell lines as Ba/F3 but also in the pathogenesis of the disease.We could
show that Tpo-independent growth of megakaryocytic progenitors,
which is a hallmark of CALR-mutatedMPNs, is inhibited when TpoR
or JAK2 are downregulated by shRNAs. This is in agreement with the
observation that patients with CALR-mutated PMF may respond to
ruxolitinib31 and with the results of the retroviral CALRmousemodel7
described in the companion paper, where the thrombocytosis was
dependent of the presence of TpoR.8
Weobserved a differential localization ofCALRmutants compared
with thewild-type.Our preliminary data indicate that activation already
occurs intracellularly for the JAK-STAT pathway, but because we
detect immatureTpoRon the cell surface alongwithCALRmutant, it is
possible that both intracellular and cell surface forms are required for
transformation.
Contrary to JAK2V617F-transformed hematopoietic cells, there
was no synergy between JAK2 and PI3-K inhibitors in inhibiting
CALR mutant cells. Interestingly, a certain degree of synergy can be
detected between JAK2 andMAP-kinase inhibitors. These differences
might relate to the precise mechanisms of activation of TpoR by
JAK2V617F vsCALRmutants.We suggest that combining JAK2 and
PI3-K inhibitors might not be effective in CALR-mutated MPNs.
Overall, our results are in agreement with CALR mutants activating
the JAK-STAT pathway with signatures that overlap,44 but are not
identical with those of JAK2V617F.45
In conclusion, this work demonstrates that CALR mutants
specifically activate TpoR in a Tpo-independent manner and bring
forward a new and unexpected oncogenic mechanism: cytokine
receptor activation by a mutated chaperone.
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Aspirant fellowships (J.-P.D., I.C., G.V.); Cliniques universitaires
St-Luc, Brussels (J.-P.D.); a Belspo postdoctoral fellowship
(V.G.); and the Austrian Science Fund (FWF: project numbers
F2812-B20 and F4702-B20) (H.N. and R.K.).
Authorship
Contribution: I.C., C.P., and M.E.-K. designed, performed, and
interpreted experiments and corrected the paper; H.N. provided
essential constructs, planned experiments, analyzed data, and
wrote the paper; R.-I.A., C.M., V.G., J.-P.D., and G.V. performed
experiments and interpreted results; A.N., A.K., and M.L.C. de-
signed, performed, and interpreted drug inhibition studies; P.J.C.
gave key input, designed fractionation and confocal microscopy
experiments, interpreted experiments, and wrote a section; H.R.
designed and interpreted experiments; and I.P., W.V., R.K.,
and S.N.C. designed and interpreted experiments and wrote the
paper.
Conflict-of-interest disclosure: The authors declare no competing
financial interests.
Correspondence: Stefan N. Constantinescu, Ludwig Institute for
Cancer Research and de Duve Institute, Université catholique de
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